2024
Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative
Leone D, Rodriguez A, Cowenhoven K, O’Connell M, Grossman M, Ferdman D. Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative. Pediatric Cardiology 2024, 1-9. PMID: 38300318, DOI: 10.1007/s00246-023-03388-3.Peer-Reviewed Original ResearchHigh-risk infantsPercentage of infantsRate of administrationPalivizumab administrationPalivizumab dosesRespiratory syncytial virus seasonHeart diseaseDose of palivizumabCongenital heart diseasePediatric cardiac patientsPalivizumab eligibilityEligible infantsPalivizumab treatmentVirus seasonPalivizumabHeart CenterCardiac patientsInfantsOxygen saturationDoseDiagnosis codesQuality improvement initiativesAdministrationBaseline rateMultidisciplinary team
2023
IMPROVING PALIVIZUMAB ADMINISTRATION TO HIGH-RISK INFANTS WITH CONGENITAL HEART DISEASE VIA A COMMUNICATION-BASED QUALITY IMPROVEMENT INITIATIVE
Leone D, Rodriguez A, Cowenhoven K, Grossman M, Ferdman D. IMPROVING PALIVIZUMAB ADMINISTRATION TO HIGH-RISK INFANTS WITH CONGENITAL HEART DISEASE VIA A COMMUNICATION-BASED QUALITY IMPROVEMENT INITIATIVE. Journal Of The American College Of Cardiology 2023, 81: 1604. DOI: 10.1016/s0735-1097(23)02048-x.Peer-Reviewed Original ResearchHigh-risk infantsQuality improvement initiativesPalivizumab administrationCongenital heartImprovement initiativesInfants